Lilly-partnered Fauna Bio plans $40M Series A to get into heart failure

Kyle LaHucik

Senior Reporter

MIAMI — Fauna Bio, a biotech that mines data on disease resistance from squirrels and other animals to create new drugs, is looking at raising a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Lilly-partnered Fauna Bio plans $40M Series A to get into heart failure

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Pfizer terminates an early-stage STING agonist trial

MoonLake's CEO on its looming mid-year pivotal readout in skin disease

Merck diversity leader to retire this summer; Geron seeks commercial chops for next CEO

Inside NYC’s waitlist-only health tech club, where young professionals find both friends and jobs

Updated: White House pulls Weldon's nomination to lead CDC at last minute

Obesity drug development—still room to grow

Lil­ly-part­nered Fau­na Bio plans $40M Se­ries A to get in­to heart fail­ure

Senior Reporter

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

Lilly-partnered Fauna Bio plans $40M Series A to get into heart failure